Connect with execs from Axios, The New York Times, Paramount and more.
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
How Bandit Running is expanding internationally while staying hyperlocal
Bandit’s focus on core running communities has helped it grow enough to start expanding outward.
Criteo is subject to a takeover bid, further proving private equity’s continued interest in ad tech
Vista Equity and Quinti Capital place a 50% premium on stock, raising questions over where the PE firms see value.
Dentsu strikes Meta deal to build plumbing for mass influencer activation
Top CMOs are assembling armies of creators, but many lack the infrastructure required to get the most out of them. A deal between Dentsu and Meta aims to fix that problem.